The Use of Spreadsheets for Pharmacokinetic Simulations by Joseph Chamberlain

“…The use of simple spreadsheets is described to create simulations of complex pharmacokinetic phenomena. The basics of spreadsheets are first described and are developed to demonstrate classical pharmacokinetics without the use of differential or integral calculus. …”
Get full text

Population Pharmacokinetics of Vancomycin in Thai Patients by Tunggul Adi Purwonugroho, Suvatna Chulavatnatol, Yupaporn Preechagoon, Busba Chindavijak, Kumthorn Malathum, Pakwan Bunuparadah

“…Population pharmacokinetics of vancomycin in Thai adult patients was determined by non-linear mixed-effects approach using 319 vancomycin serum concentrations from 212 patients. …”
Get full text

Prednisolone pharmacokinetics in dogs with protein‐losing enteropathy by Sara A. Jablonski, Jessica L. Strohmeyer, John P. Buchweitz, Andreas F. Lehner, Daniel K. Langlois

“…Objective To compare pharmacokinetics (PK) of orally administered prednisolone in dogs with PLE vs healthy controls. …”
Get full text

Pharmacokinetics of PEGylated Recombinant Human Erythropoietin in Rats by Xiaohan Cao, Zhiyong Chen, Zhuoran Yu, Yonghong Ge, Xianyin Zeng

“…Due to its short half-life, the main aim for this pharmacokinetic study is to investigate a newly developed PEG-rHuEPO with large molecular weight in SD rats. …”
Get full text

Pharmacokinetics of Anti-Epileptic Drugs and their Clinical Significance by Svein I. Johannessen

“…OXC seems to lack several disadavantageous pharmacokinetic properties common to other major anti-epileptic drugs. …”
Get full text

Pharmacokinetics and Biodistribution of Zinc-Enriched Yeast in Rats by Shuangqing Zhang, Yan Zhang, Ning Peng, Haibo Zhang, Juan Yao, Zhihong Li, Liegang Liu

“…The purpose of the investigation was to compare and evaluate pharmacokinetics and biodistribution of ZnY and ZnSO4 in rats. …”
Get full text

Pharmacokinetic Interactions between Cardiovascular Medicines and Plant Products by Irina-Iuliana Costache, Anca Miron, Monica Hăncianu, Viviana Aursulesei, Alexandru Dan Costache, Ana Clara Aprotosoaie

“…Numerous studies and case reports showed various pharmacokinetic interactions that are characterized by a high degree of unpredictability. …”
Get full text

Pharmacokinetics of Hyperthermic Intrathoracic Chemotherapy following Pleurectomy and Decortication by Paul H. Sugarbaker, O. Anthony Stuart, Christopher Eger

“…We monitored the intrapleural and plasma levels of mitomycin C and doxorubicin by HPLC assay in order to determine the pharmacokinetic behavior of this intracavitary use of chemotherapy. …”
Get full text

Pharmacokinetic comparisons of S-oxiracetam and R-oxiracetam in beagle dogs by Wang Wusan, Ji Hui, Li Tingting, Jia Yuanwei, Xie Haitang

Subjects: Get full text

Clinical Pharmacokinetics of Atogepant in Healthy Japanese and White Adults by Ramesh R. Boinpally, Brian McNamee

Subjects: Get full text

A physiologically-based pharmacokinetic model for the antibiotic ertapenem by Michele L. Joyner, Cammey C. Manning, Whitney Forbes, Michelle Maiden, Ariel N. Nikas

Subjects: “…physiologically based pharmacokinetic model (pbpk)…”
Get full text

Update on a Pharmacokinetic-Centric Alternative Tier II Program for MMT—Part II: Physiologically Based Pharmacokinetic Modeling and Manganese Risk Assessment by Michael D. Taylor, Harvey J. Clewell, Melvin E. Andersen, Jeffry D. Schroeter, Miyoung Yoon, Athena M. Keene, David C. Dorman

“…Recently, a variety of physiologically based pharmacokinetic (PBPK) models have been developed for the essential element manganese. …”
Get full text

Isoniazid urine spectrophotometry for prediction of serum pharmacokinetics in adults with TB by P. S. Rao, K. Reed, N. Modi, D. Handler, K. Petros de Guex, S. Yu, L. Kagan, R. Reiss, N. Narayanan, C. A. Peloquin, A. Lardizabal, C. Vinnard, T. A. Thomas, Y. L. Xie, S. K. Heysell

“…BACKGROUND: Isoniazid (INH) is an important drug in many TB regimens, and unfavorable treatment outcomes can be caused by suboptimal pharmacokinetics. Dose adjustment can be personalized by measuring peak serum concentrations; however, the process involves cold-chain preservation and laboratory techniques such as liquid chromatography (LC)/mass spectrometry (MS), which are unavailable in many high-burden settings. …”
Get full text

Analysis of HIV therapy in the liver using optimal control and pharmacokinetics by Hasifa Nampala, Matylda Jabłońska-Sabuka, Martin Singull

Subjects: Get full text

Pharmacokinetics and pharmacodynamics of ciprofol after continuous infusion in elderly patients by Xiaowen Guo, Yang Qiao, Sijie Yin, Fengqin Luo, Lingmei Yi, Jiajia Chen, Man Lu

Subjects: Get full text

Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals by Jacinta Nwamaka Nwogu, Qing Ma, Chinedum Peace Babalola, Waheed Adeola Adedeji, Gene D. Morse, Babafemi Taiwo

“…Other factors are related to pharmacokinetics and pharmacogenetics of the specific ARV agent or mediated by drug interactions, local inflammation, and blood flow. …”
Get full text

Pharmaceutical, Pharmacokinetic and Other Considerations for Intravenous to Oral Stepdown Therapy by Peter J Jewesson

“…Recognition of the pharmacokinetic characteristics of these oral agents is essential lo successful therapy. …”
Get full text

Pharmacokinetics of Hydrogen During Hydrogen-Saturated Saline Infusion in Pigs by Masaki Shibuya, Masafumi Fujinaka, Mako Yonezawa, Natsumi Nishimura, Hitoshi Uchinoumi, Hiroshi Sunahara, Kenji Tani, Eiji Kobayashi, Motoaki Sano

“…Here, we verified the pharmacokinetics of hydrogen after the infusion of hydrogen-saturated saline. …”
Get full text

Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors by Guihong Yang, Yimei Wang, Huimin Zhao, Ziyi Jiang, Shansong Zheng, Mingjing Ge, Meimei Si, Xiaoyan Kang

“…Abstract Iruplinalkib (WX‐0593), a selective oral ALK/ROS1 tyrosine kinase inhibitor, was approved in China as first‐line therapy for ALK‐positive non‐small‐cell lung cancer (NSCLC) and for the treatment of locally advanced or metastatic ALK‐positive NSCLC that has progressed following crizotinib therapy. Pharmacokinetics (PK) data of iruplinalkib have been collected in healthy subjects and patient populations in several studies. …”
Get full text